LYMPHANGIOSIS CARCINOMATOSA

This adverse event was reported 1042 times

These drugs are most commonly taken by patients reporting LYMPHANGIOSIS CARCINOMATOSA:

# Drug Count
0 CARBOPLATIN 104
1 PACLITAXEL 82
2 TRASTUZUMAB 81
3 PEMBROLIZUMAB 79
4 BEVACIZUMAB 77
5 CAPECITABINE 77
6 EVEROLIMUS 74
7 PACLITAXEL (AIBUMIN-BOUND) 74
8 NIVOLUMAB 73
9 LETROZOLE 70
See all common drugs associated with LYMPHANGIOSIS CARCINOMATOSA

LYMPHANGIOSIS CARCINOMATOSA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 GEFITINIB 43 0.0048
1 AFATINIB 27 0.0041
2 DACOMITINIB 3 0.0040
3 VINORELBINE 23 0.0033
4 NALDEMEDINE 5 0.0030
5 BELZUTIFAN 5 0.0028
6 ERIBULIN MESYLATE 10 0.0027
7 CERITINIB 6 0.0025
8 ADO-TRASTUZUMAB EMTANSINE 21 0.0025
9 DATOPOTAMAB DERUXTECAN 2 0.0023
See all drugs enriched for association with LYMPHANGIOSIS CARCINOMATOSA